Nod for schizophrenia drug with no jitters
The US drugs regulator approves Caplyta, which in trials did not cause uncomfortable akathisia sensations
23 December 2019 - 15:10
The US Food and Drug Administration (FDA) has approved Intra-Cellular Therapies’s investigational drug to treat schizophrenia, the company said on Monday, sending its shares soaring 40%.
The treatment, Caplyta, is the drug developer’s lead candidate that has shown to regulate three neurotransmitter systems — serotonin, dopamine and glutamate — linked to severe mental illnesses. The approval comes with a boxed warning, the FDA’s harshest, saying the drug is not for the treatment of patients with dementia-related psychosis...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.